Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $52.1 million.

  • Haemonetics' Accumulated Expenses rose 1342.39% to $52.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $52.1 million, marking a year-over-year increase of 1342.39%. This contributed to the annual value of $59.4 million for FY2025, which is 2637.29% down from last year.
  • According to the latest figures from Q4 2025, Haemonetics' Accumulated Expenses is $52.1 million, which was up 1342.39% from $48.3 million recorded in Q3 2025.
  • Haemonetics' 5-year Accumulated Expenses high stood at $80.7 million for Q1 2024, and its period low was $30.4 million during Q3 2022.
  • Moreover, its 5-year median value for Accumulated Expenses was $46.8 million (2021), whereas its average is $47.6 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 4051.53% in 2021, then plummeted by 2637.29% in 2025.
  • Haemonetics' Accumulated Expenses (Quarter) stood at $41.1 million in 2021, then grew by 27.07% to $52.2 million in 2022, then grew by 12.61% to $58.8 million in 2023, then fell by 21.83% to $45.9 million in 2024, then grew by 13.42% to $52.1 million in 2025.
  • Its Accumulated Expenses stands at $52.1 million for Q4 2025, versus $48.3 million for Q3 2025 and $35.8 million for Q2 2025.